27Sep 2023
Hs-Cardiac Troponin I–Guided Therapy to Prevent Anthracycline Cardiotoxicity

Hs-Cardiac Troponin I–Guided Therapy to Prevent Anthracycline Cardiotoxicity

This study monitored patients receiving anthracycline chemotherapy for breast cancer and non-Hodgkin lymphoma for cardiotoxicity using cardiac troponin testing and cardiac MRI. Those at high risk of cardiotoxicity received a combination of candesartan and carvedilol therapy, but it showed no cardioprotective effect. Low-risk patients also experienced declines in left ventricular ejection fraction, questioning the utility of routine cardiac troponin monitoring.

  • #cardiology

Like

Save

Share